Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Zacks Investment Research on MSN
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline ...
Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
A Jacobs School of Medicine and Biomedical Sciences faculty member is senior author on a newly published study on the public health challenges of HIV in Nigeria.
Parents with HIV who want to breastfeed are now able to — with the blessing of their pediatrician — after a game-changing report was released this spring. The 11-page report, “Infant Feeding for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback